Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $28.89

Arcus Biosciences, Inc. (NYSE:RCUS) has been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $28.8889.

Several analysts have issued reports on the company. Truist Financial set a $30.00 price target on Arcus Biosciences in a research note on Friday, December 12th. Wells Fargo & Company increased their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 20th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Wedbush set a $35.00 price target on Arcus Biosciences and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group raised their price target on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 82,997 shares of Arcus Biosciences stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the sale, the president directly owned 954,063 shares in the company, valued at approximately $23,574,896.73. The trade was a 8.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert C. Goeltz II sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the sale, the chief financial officer directly owned 92,138 shares in the company, valued at $1,842,760. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 294,193 shares of company stock worth $6,098,761 in the last three months. 9.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in Arcus Biosciences by 59.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in shares of Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the last quarter. CWM LLC increased its holdings in shares of Arcus Biosciences by 233.6% during the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after acquiring an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after acquiring an additional 1,796 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Arcus Biosciences by 440.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after purchasing an additional 6,191 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Stock Up 0.3%

Arcus Biosciences stock opened at $22.27 on Monday. The stock has a market capitalization of $2.40 billion, a PE ratio of -6.47 and a beta of 0.75. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average of $20.82 and a 200-day moving average of $13.98.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The business had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm’s quarterly revenue was down 45.8% on a year-over-year basis. During the same period last year, the business posted ($1.00) earnings per share. On average, equities research analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.